A post-hoc analysis of the PACIFIC trial found baseline proton pump inhibitor (PPI) use was associated with worse progression-free and overall survival in patients receiving consolidative durvalumab for stage III NSCLC. Similar negative findings for PFS were also noted with antibiotic use, raising questions about the impact of concomitant medications on immunotherapy efficacy.
“with durvalumab, PFS 9.4m vs 17.2m with no PPI (HR 1.57) and OS 33m vs 57.9m (HR 1.66). No difference with placebo.”
— @StephenVLiu · PPIs and durvalumab efficacy · View post ↗📌 Amplified by @KolPulseAI
The breast oncology community is discussing the role of genomic assays, such as Oncotype DX, in assessing recurrence risk, noting instances where genomic biology differs significantly from microscopic anatomy. A meta-analysis also shows that Trop-2 antibody-drug conjugates (ADCs) provide the greatest PFS benefit in patients with Trop-2–high metastatic breast cancer, leading to calls for standardized Trop-2 assays.
“📖Our @JNCI_Now meta-analysis of randomized trials shows that Trop-2 ADCs provide the greatest PFS benefit in Trop-2–high MBC”
— @CarmineDeA1 · Trop-2 ADC Efficacy · View post ↗
“The microscope saw anatomy. The genome saw biology. Two different languages.”
— @IbrahimManff · Genomic vs. Anatomic Pathology · View post ↗The GI oncology community is discussing the negative results of the PERISCOPE II trial, which showed gastrectomy plus CRS/HIPEC provided no survival benefit over systemic therapy for gastric cancer with peritoneal metastases. In contrast, 4-year follow-up data from the TOPAZ-1 trial confirmed a sustained overall survival benefit for durvalumab plus chemotherapy in advanced biliary tract cancer. Other topics include new Pan-Asian adapted ESMO guidelines for HCC and a Phase II trial of FTD/TPI plus ramucirumab in later-line gastric cancer.
“PERISCOPE II: In gastric cancer with peritoneal metastases, gastrectomy plus CRS/HIPEC provided no survival benefit over systemic therapy!!”
— @dr_yakupergun · PERISCOPE II trial · View post ↗📌 Amplified by @KolPulseAI
“🚨 HCC treatment is no longer a simple BCLC flowchart. It’s now a branching decision tree of transplant, locoregional therapy, immunotherapy, and sequencing.”
— @DrRishabhOnco · HCC guidelines · View post ↗
“Safety consistent, no new signals”
— @hongjaechon · TOPAZ-1 trial · View post ↗
“This Phase II trial of FTD/TPI + ramucirumab offers a viable path forward: 76.9% DCR, 4.0-mo median TTF, & manageable safety (mainly neutropenia).”
— @JCOOA_ASCO · Later-line gastric cancer · View post ↗The GU oncology community is discussing the new FDA approval of perioperative enfortumab vedotin plus pembrolizumab for muscle-invasive bladder cancer (MIBC), based on data from KEYNOTE-B15/EV-304. Also noted is the ANZUP 1301 trial in NMIBC, where adding mitomycin to BCG did not improve DFS but did reduce the total BCG dose administered. Other topics include new Prostate Cancer Working Group 4 (PCWG4) recommendations and a new AI-based biomarker for mHSPC.
“But the combination used 39% ⬇️BCG doses (median 9 vs 16) & more patients completed their planned treatment (78% vs 68%)”
— @LauraBukavinaMD · ANZUP 1301 in NMIBC · View post ↗
“The FDA approval of perioperative EVP in muscle invasive bladder cancer makes platinum eligable somewhat redundant. It creates a paradigm shift in the disease and a is landmark moment .”
— @tompowles1 · EV+Pembrolizumab Approval · View post ↗
“- 2yr EFS: 79.4% vs. 66.2% (HR: 0.53) - 2yr OS: 86.9% vs. 81.3% (HR: 0.65) - pCR: 55.8% vs. 32.5%”
— @OncBrothers · KEYNOTE-B15/EV-304 Data · View post ↗📌 Amplified by @KolPulseAI
The myeloma/hematology community is discussing the new FDA approval for a subcutaneous formulation of isatuximab with an on-body delivery system. The approval covers its use with VRd in newly diagnosed multiple myeloma (NDMM) and with Pd or Kd in relapsed/refractory (RRMM) settings. Some commentary questioned whether subcutaneous formulations consistently deliver the expected time-saving conveniences in practice.
“Isatuximab subcutaneously with the on-body delivery system is now @US_FDA ✅ for multiple myeloma”
— @OncBrothers · Subcutaneous isatuximab approval · View post ↗📌 Amplified by @KolPulseAI
“Nice to see subQ isatuximab approved! *But* reminds me of this study👇 from @majorajay- subQ forms (this was for BsAbs) didn’t lead to the time convenience I would have expected”
— @CharlesMilrod · Subcutaneous formulation convenience · View post ↗📌 Amplified by @KolPulseAI
The hematology community is discussing the FDA approval of nivolumab plus chemotherapy for previously untreated, advanced-stage classic Hodgkin lymphoma. Additionally, new data from the BRUIN CLL-322 trial, published in The Lancet, shows a progression-free survival benefit for the pirtobrutinib-containing PVR regimen over VR in relapsed/refractory CLL. In AML, a new prognostic model, PRISM-AML, has been developed for overall survival following HMA+venetoclax therapy.
“@US_FDA has approved nivolumab plus chemotherapy for adults and adolescents with previously untreated advanced-stage classic Hodgkin lymphoma.”
— @JournalCancer · Nivolumab in cHL · View post ↗
“Marked PFS ⬆️ for PVR over VR in RR #CLL esp. seen post covBTKi resistance, TP53 mut. subgroups.”
— @tobyeyre82 · BRUIN CLL-322 · View post ↗📌 Amplified by @KolPulseAI
“With PRISM-AML, we built a large multinational database (N=2,092) to generate a high-fidelity, reproducible prognostic model for OS integrating clinical, cytogenetic, and mutation data.”
— @CLachowiez · PRISM-AML Model · View post ↗
“Excited to share that our team at King’s College London has been awarded a £1M MRC Partnership Grant to lead the international i4MDS consortium.”
— @SKordasti · i4MDS Consortium · View post ↗